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Abstract 
Cullin-RING ubiquitin ligases (CRLs) responsible for substrate specificity of ubiquitination and play 
a key role in cell-cycle control and DNA damage response. In this study, we assessed associations 
between 16,599 SNPs in 115 CRL genes and lung cancer risk by using summary data of six 
published genome-wide association studies (GWASs) of 12,160 cases and 16,838 cases of 
European ancestry. As a result, we identified three independent SNPs in DCAF4 (rs117781739, 
rs12587742 and rs2240980) associated with lung cancer risk (odds ratio = 0.91, 1.09 and 1.09, 
respectively; 95% confidence interval = 0.88-0.95, 1.05-1.14 and 1.05-1.13, respectively; and P = 
3.99×10-6, 4.97×10-5 and 1.44×10-5, respectively) after multiple comparison correction by a false 
discovery rate <0.05. Since SNP rs12587742 is located within the promoter region and one CpG 
island of DCAF4, we further performed in silico functional analyses and found that the rs12587742 
variant A allele was associated with an increased mRNA expression (P = 2.20x10-16, 1.79x10-13 and 
0.001 in blood cells, normal lung tissues and tumor tissues of lung squamous carcinoma, 
respectively) and a decreased methylation status (P = 2.48x10-9 and 0.032 in adipose and lung 
tumor tissues, respectively). Moreover, evidence from differential expression analyses further 
supported oncogenic effect of DCAF4 on lung cancer, with higher mRNA levels in both lung 
squamous carcinoma and adenocarcinoma (P = 4.48x10-11 and 1.22x10-9, respectively) than in 
adjacent normal tissues. Taken together, our results suggest that rs12587742 is associated with 
increased lung cancer risk, possibly by up-regulating mRNA expression and decreasing methylation 
status of DCAF4.   
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Summary  
 
By using meta-analysis and in silico functional analysis, we identified one functional SNP 
rs12587742 within the CpG island of DCAF4, associated with lung cancer risk, possibly by 
decreasing methylation status and up-regulating mRNA expression of DCAF4.   
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Introduction 
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in 
the world. In USA, the estimated incidence of lung cancer in 2016 is 57.3 per 100,000 with an 
estimated mortality of 46 per 100,000 (1). Etiology studies have revealed several environmental 
risk factors for lung cancer, such as exposures to cigarette smoke, radon, asbestos, and arsenic 
(2). Genetic factors such as heritable and somatic mutations are also involved in the etiology of 
lung cancer. Multiple genetic loci with moderate effects have also been reported by genome-
wide association studies (GWASs) of lung cancer at chromosome regions of 3q28, 5p15.33, 
6p21.33, 6p22.1, 13q13.1, 15q25.1 and 22q12.1 in European populations (3-8). However, most 
of the published GWASs had mainly focused on SNPs that reached genome-wide significance, 
most of which did not have clear biological functions (9). In the post-GWAS era, identification of 
genetic variants with moderate but detectable effects and potential biological functions might 
provide additional insight about the complex mechanisms of cancer development. Currently, the 
availability of enormous genetic data made such studies feasible (8).  
Carcinogenesis is a multiple-step process that often involves loss control of cell proliferation. 
The ubiquitin-proteasome system (UPS) is a major player in the regulation of critical cellular 
processes, including cell proliferation, differentiation and apoptosis.  Dysfunction of the system 
has been implicated in several clinical disorders including inflammation and cancer (10,11). 
There are three types of enzymes that specifically mediate ubiquitin attachment to the target 
proteins: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin 
ligases (E3s). In humans, there are only 2 E1s, at least 38 E2s and over 600 kinds of E3. Cullin-
RING ubiquitin ligases (CRLs) represent one of the largest classes of E3 ubiquitin ligases 
mainly responsible for the substrate-specific ubiquitination. In addition, CRLs play a key role in 
cell-cycle control and DNA damage response (12), and deregulation of CRLs may lead to 
abnormal cell proliferation and genomic instability, which in turn could result in malignance 
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transformation. Currently, several components of CRLs (e.g., SKP2, CUL4A, CUL1 and RBX1/2) 
have been found to behave as oncogenes and are frequently amplified or overexpressed in 
human cancers, while several others (e.g., FBXW7 and VHL) act as suppressor genes for they 
were often mutated or inactivated in cancers (13-15). Notably, as one of the most studied CRLs, 
SKP2 is found to be overexpressed and associated with aggressiveness and metastasis of non-
small cell lung cancer (NSCLC), as a result of accelerated degradation of a cell-cycle inhibitor 
p27 (16,17). Moreover, large-scale somatic mutations of KEAP1, another well-studied CRL, 
occurred in multiple human cancers, including NSCLC (18). According to the findings of these 
previous studies, we hypothesize that genetic variants with potential functions in genes 
encoding CRLs are associated with risk of lung cancer. 
To test our hypothesis, we first performed a meta-analysis for SNPs in CRL-related genes by 
using summary statistics from six published lung cancer GWASs, including 12,160 cases and 
16,838 controls from the TRICL-ILCCO Consortium (Transdisciplinary Research for Cancer in 
Lung of the International Lung Cancer Consortium) (19). For those identified SNPs as significant, 
we further performed stratified analysis by smoking status and histological types and 
investigated their effects on gene expression and methylation in cell lines and tissues by using 
the available genomic and genetic data from multiple public databases (e.g, TCGA and GTEx).  
Materials and methods 
Study populations 
The study populations included in the present study have been detailed in previous publications 
from TRICL and ILCCO (8,19). Briefly, six published lung cancer GWASs were obtained from 
the TRICL-ILCCO consortium, which consists of 12,160 lung cancer cases and 16,838 controls 
of European descent. The GWAS participants included Institute of Cancer Research (ICR), The 
University of Texas MD Anderson Cancer Center (MDACC), International Agency for Research 
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on Cancer (IARC), National Cancer Institute (NCI), Lunenfeld-Tanenbaum Research Institute 
study (Toronto), and German Lung Cancer Study (GLC). Two additional GWAS data sets were 
also requested from other independent GWASs of Caucasian populations: the Harvard Lung 
Cancer Study (984 cases and 970 controls) and Icelandic Lung Cancer Study (deCODE) (1,319 
cases and 26,380 controls) from the ILCCO (20,21). A written informed consent was obtained 
from each participant of each GWAS. The present study was approved by Duke University 
Health System Institutional Review Board and all methods performed in this study were in 
accordance with the relevant guidelines and regulations.  
Genotyping platforms and quality controls 
For all the GWAS datasets, multiple genotyping platforms were applied, including Illumina 
HumanHap 317, 317+240S, 370Duo, 550, 610 or 1M arrays (22). For the meta-analyses, 
imputation was performed based on the reference data from the 1000 Genomes Project (phase 
I integrated release 3, March 2012) by using IMPUTE2 v2.1.1 (23), MaCH v1.0 (24) or minimac 
(version 2012.10.3) software. Only SNPs with an information score ≥ 0.40 in IMPUTE2 or an r2 
≥ 0.30 in MaCH were included in the final analyses. Standard quality control on samples was 
performed on all scans, excluding individuals with a low call rate (< 90%), extremely high or low 
heterozygosity (P < 1.0 × 10−4) and non-European ancestry (using the HapMap phase II CEU, 
JPT/CHB and YRI populations as a reference). 
Gene and SNP selection 
The CRL-related genes were collected from the category of “Cullin-RING ubiquitin ligase 
complex” in the Gene Ontology database 
(http://amigo.geneontology.org/amigo/term/GO:0031461). In total, we retrieved 118 genes from 
the database, 115 of which were located in autosomal genes (listed in Supplementary Table 1). 
We then mapped all the SNPs located within 2 KB up- and down-stream of the NCBI Reference 
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sequence of those selected genes and extracted their summary data from the GWAS datasets. 
SNPs included in the final meta-analysis were those with call rate ≥ 90%, minor allele frequency 
≥ 1%, and P value for the Hardy Weinberg Equilibrium test ≥ 10-5. All remained SNPs also 
passed the quality control of imputation with info ≥ 0.40 in IMPUTE2 or an r2 ≥ 0.30 in MaCH.  
In-silico functional analysis as a biological validation 
For those identified SNPs as significant, we first performed bioinformatic functional prediction by 
using three online tools: SNPinfo (http://snpinfo.niehs.nih.gov), RegulomeDB 
(http://www.regulomedb.org) and HaploReg 
(http://archive.broadinstitute.org/mammals/haploreg/ haploreg.php). We then performed 
expression quantitative trait loci (eQTL) analysis by using data from multiple sources: 
lymphoblastoid cell data of 373 European individuals from Genetic European Variation in Health 
and Disease Consortium (GEUVADIS) and the 1000 Genomes Project (phase I integrated 
release 3, March 2012) (25); lung tissues data from the Genotype-Tissue Expression (GTEx) 
project (26); tumor tissues and adjacent normal tissue data from the Cancer Genome Atlas 
(TCGA) database (27,28). SNP-methylation correction analysis was further performed by using 
the data from TCGA and the Multiple Tissue Human Expression Resource (MuTHER) project 
implemented in the Genevar software (29). Different expression analyzes between tumor and 
normal tissues were also performed for those identified genes using the data from TCGA and 
Oncomine (https://www.oncomine.org ). The TCGA level 3 RNAseq data 
(LUSC_rnaseqv2_Level_3_RSEM_genes_normalized_data.2016012800.0.0.tar.gz and 
LUAD_Level_3_RSEM_genes_normalized_data_2016012800.0.0.tar.gz) and methylation data 
(gdac.broadinstitute.org_LUSC.Methylation_Preprocess.Level_3.2016012800.0.0.tar.gz and 
gdac.broadinstitute.org_LUAD.Methylation_Preprocess.Level_3.2016012800.0.0) were 
obtained from the Broad TCGA GDAC site (http://gdac.broadinstitute.org).  
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Statistical methods 
For each GWAS data set, we performed an unconditional logistic regression to estimate odds 
ratios (ORs) and 95% confidence intervals (CIs) per effect allele by using R (v2.6), Stata (v10, 
State College, Texas, US) and PLINK (v1.06) software with adjustment for the top significant 
principle components (8). We performed meta-analysis by the inverse variance method using a 
fixed effects model (30). If the Cochran's Q Test P-value > 0.100 or the heterogeneity statistic (I2) 
< 25%, a random-effects model was employed. We used the linear step-up method of Benjamini 
and Hochberg to calculate false discovery rate (FDR) with a cut-off value of 0.05 to correct for 
multiple comparisons (31) and used linear regression for the eQTL analysis and paired t-test for 
the gene differential expression analysis between tumor and adjacent normal tissues. For the 
differential expression and mRNA-methylation correlation analyses, outliers were defined as 
those outside the interval (Q1 -3×IQR, Q3 +3×IQR) and were removed in the final analysis. Q1 
and Q3 denote the first and third quartiles, respectively and IQR denotes the interquartile range. 
Based on the 1000 Genomes European (EUR) reference data (phase I integrated release 3, 
March 2012), we used LocusZoom (32) and Haploview v4.2 (33) to construct the regional 
association plots and linkage disequilibrium (LD) plots, respectively. SNP pruning was applied, 
and SNPs with paired-wise r2 < 0.30 were considered as independent. All other analyses were 
conducted with SAS (version 9.4; SAS Institute, Cary, NC, USA), if not mentioned specifically. 
Results 
Meta-analysis of the main effects 
The sample sizes for the eight GWASs included in the present study are summarized in 
Supplementary Table 2, and the workflow of this study is depicted in Figure 1. We first 
performed meta-analysis using summary statistics from six GWASs (i.e., ICR, MDACC, IARC, 
NCI, Toronto and GLC) including 12,160 lung cancer cases and 16,838 non-cancer controls. 
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The overview of the overall association results is shown in the Manhattan plot (Figure 2a). We 
found there were 84 SNPs of 10 CRL-encoding genes with a nominal P < 0.001, 28 of which are 
in the DCAF4 gene with FDR < 0.05. More detailed information for each of the 84 SNPs 
(including position, effect allele, relative minor allelic frequency, effect sizes, unadjusted and 
FDR adjusted P-values, and heterogeneity test results) is summarized in Supplementary Table 
3. The regional association plots (Fig 2b) demonstrated that the top SNP rs72734410 of DCAF4 
was in moderate to high LD with other SNPs of the same gene but in very low LD (r2 < 0.2) with 
the top SNP rs214278 in the neighboring gene PSEN1.  
We then performed functional prediction for these 28 significant SNPs by u ing three 
bioinformatics tools (SNPinfo, regulomDB and HaploReg) and selected those apparently 
independent SNPs (paired-wise r2 < 0.3) with potential effects on gene expression or functions 
for further analysis. As a result, two SNPs (rs17781739 and rs2240980) together with another 
functional SNP rs12587742 were chosen in further analysis (Fig 2c-2e). As shown in Table 1, 
SNP rs17781739 G>T was associated with a significantly decreased risk of lung cancer (OR = 
0.91, 95% CI = 0.88 – 0.95, P = 3.99 × 10-6), while two other SNPs in moderate LD (pair-wise r2 
= 0.38) were associated with a significantly increased lung cancer risk (rs12587742 G>A: OR = 
1.09, 95% CI = 1.05 – 1.14, P = 4.97 × 10-5; and rs2240980 C>G: OR = 1.08, 95% CI = 1.05 – 
1.14, P = 1.44 × 10-5). There was no heterogeneity observed for the effect estimates of these 
three SNPs from the six GWASs (Table 1).  
We then expanded the meta-analysis for these three identified SNPs by including two additional 
GWASs with European descents from Harvard University (984 cases and 970 controls) and 
deCODE (1,319 cases and 26,380 controls) as a population validation, and similar results were 
observed (Table 2).  
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Stratified analyses 
As lung adenocarcinoma and squamous cell carcinoma may have different risk factors, we 
performed stratified analysis by these histological types. By using 4862 adenocarcinomas and 
3897 squamous cell carcinomas from all the eight GWASs (supplementary table 1), we found 
that the effect of rs1258772 was more significant in squamous cell carcinomas (OR = 1.12, 95% 
CI = 1.05 – 1.20, P = 4.16 × 10-4) than in adenocarcinomas (OR = 1.08, 95% CI = 1.02 – 1.15, P 
= 0.010), while SNP rs2240980 had more significant effects in adenocarcinomas (OR = 1.10, 95% 
CI = 1.04 – 1.15, P = 3.44 × 10-4) than in squamous cell carcinomas (OR = 1.07, 95% CI = 1.01 
– 1.13, P = 0.017) (Table 2). However, heterogeneity test showed that the effect difference 
between two histological strata was non-significant for both SNPs.  
Cigarette smoking is one of the major risk factors for lung cancer and may interact with genetic 
factors. According to the currently available smoking data, study subjects were divided into two 
groups: ever smokers (defined as individuals having smoked at least 100 cigarettes in their 
lifetime) and never smokers. We performed stratified analysis by smoking status and found that 
only SNP rs17781739 had a significant effect in ever smokers (OR = 0.92, 95% CI = 0.88-0.96, 
P = 3.31 × 10-4) (Table 2). No significant association was observed in never smokers for all 
three SNPs, which might be due to a reduced sample size (731 never smokers). The forest 
plots of the overall and stratification results for these three SNPs are shown in Supplementary 
Fig 1a-c. 
In silico functional validation 
The three SNPs were predicted with potentials to influence mRNA transcription (Table 1 and 
Fig 2d, 2e). According to experimental data (e.g., histone modification, DNase cluster, 
transcription factor binding, RNAseq) from the ENCODE project (Fig 2d), we found that two 
SNPs (rs17781739 and rs12587742) are located within one CpG island with strong signals for 
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active enhancer and promoter functions (indicated by DNase hypersensitivity and histone 
modification H3K27 acetylation, and H3K4 tri-methylation, respectively). Further transcription 
factor binding analysis (using the transcription factor ChIP-seq data) showed that rs12587742 is 
located at the c-MYC motif as shown by the position weight matrix (PWM) based Sequence 
Logo (Fig 2e), and the allele difference might influence the binding activity of the transcription 
factor. SNP rs2240980 was also predicted to be located at a regulatory region with evidence 
from DNase cluster and transcription factor CHIP-seq data (Fig 2d).   
As genotyping data for the three identified SNPs were not available in the TCGA database, we 
performed imputation for them by using the reference data from the 1000 Genomes project. 
Further eQTL and meQTL analyses were conducted for SNPs with high quality imputation. Only 
SNPs from patients with lung squamous carcinoma passed the imputation quality control 
(imputation info > 0.9) and were used in further SNP-expression/methylation correlation analysis. 
As shown in Fig 3a, 3d and 3g, all of those three SNPs had a significant correlation with the 
mRNA expression of DCAF4 in the blood cells from 373 Europeans individuals (P = 7.85x10-10, 
2.20x10-16 and 8.76x10-6 for rs17781739, rs12587742 and rs2240980, respectively). When put 
all these three SNPs into the same regression model, only SNP rs1258772 and rs2240980 
remained significant (P =0.208, 5.86 x10-25 and 0.003 for rs17781739, rs12587742 and 
rs2240980, respectively). These results suggest that two SNPs (rs1258772 and rs2240980) in 
DCAF4, particularly rs1258772, have an independent effect on the gene expression. 
We also performed SNP and mRNA expression correlation analysis by using the expression 
data in tumor tissues from 182 lung squamous cell carcinomas from TCGA database (Fig 3b, 
3e and 3h). Once again, only SNP rs12587742 showed a significant correlation with increased 
mRNA expression of DCAF4 (P = 0.001). Such correlation was also supported by the results 
from normal lung tissues (P = 1.79x10-13) (Supplementary Fig 2a) as well as multiple other 
tissues (e.g., testis, skin, colon, esophagus, subcutaneous adipose, stomach, pancreas, breast 
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and thyroid) based on the data from the GTEx project (Supplementary Table 4). Based on 
those results, the rs12587742 “A” allele was associated with an increased mRNA expression of 
DCAF4 in most tissues except for testis. Considering this SNP is located within one CpG island, 
we further explored its influence on the methylation status of DCAF4 by using the data from 
TCGA and the MuTHER project. We observed that the “A” allele was associated with a 
decreased methylation status (beta value, which is defined as the ratio of methylated probe 
intensity and the sum of methylated and un-methylated probe intensities) in the tumor tissues 
from 157 lung squamous cell carcinomas (Fig 3f, P = 0.032) and the adipose tissues from 428 
female twin-pairs (Supplementary Fig 2b, P = 2.48x10-9) (34). No significance was observed 
for two other SNPs (rs17781739 and rs2240980) to be associated with mRNA expression (Fig 
3b and 3h) and methylation in the tumor tissues (Fig 3c and 3i). However, it should be noted 
that two other SNPs (rs2302587 and rs9788482) that had a moderate to relatively high LD with 
rs17781739 and rs2240980 (r2 = 0.73 and 0.43, respectively) showed a significant correlation 
with the methylation status in the adipose tissues from the female twin-pairs (Supplementary 
Fig 2c and 2d).  
Differential expression analyses revealed that the DCAF4 gene had higher mRNA expression in 
tumor tissues from 156 lung squamous cell carcinomas and 238 adenocarcinomas (P = 4.48 x 
10-11 and 1.22 x 10-9) than in adjacent normal tissues (Fig 4a and 4b). Results from other 
studies collected in the cancer microarray database Oncomine also showed some evidence for 
a high expression level of DCAF4 in lung adenocarcinomas than in the normal tissues 
(Supplementary Fig 3a and 3b). We also observed a significantly negative correlation between 
the DCAF4 methylation status and mRNA expression levels in tumor tissues from both lung 
squamous cell carcinomas and adenocarcinomas (P = 0.070 and 8.22 x 10-6, respectively) (Fig 
4c and 4d), which suggests that a high methylation status may led to a decrease in mRNA 
expression of DCAF4 in the target tissues.  
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We finally investigated the mutations of DCAF4 in lung tumor tissues by using the public 
available data from the database of the cBioPortal for Cancer Genomics 
(http://www.cbioportal.org). As shown in Supplementary Fig 4, this gene had low somatic 
mutation rates in both the lung adenocarcinoma (LUAD; mutation rate = 0.5% [1/183], 5.9% 
[2/34], 0.4% [1/230] and 0% [0/163] in the Broad, MSKCC, TCGA and TSP studies, respectively) 
and squamous cell carcinoma (LUSC; mutation rate = 1.1% [2/178] in the TCGA study). Such 
results suggested the functional SNPs in DCAF4 might play more important role in the 
dysregulation of mRNA expression and methylation than mutations in tumor tissues.      
Discussion 
In the present study, we performed an extensive analysis for associations between SNPs in 115 
CRL-related genes and lung cancer risk by combining the summary data of six GWASs from the 
TRICL-ILLCO consortium including 12,160 cases and 16,838 cases. Such a large sample size 
allowed us to identify novel susceptibility loci with some moderate effects, which would have 
been often omitted in previous single GWAS. As a result, we identified three independent, 
potentially functional DCAF4 SNPs (rs117781739, rs12587742 and rs2240980) that were 
significantly associated with lung cancer risk in European populations. Further functional 
prediction analyses using data from blood cells and tumor tissues from the LUSC database 
revealed that the rs12587742 variant A allele was associated with an increased mRNA 
expression and a decreased methylation status of DCAF4. In addition, higher mRNA expression 
level of DCAF4 was also observed in tumor tissues than in adjacent normal tissues from 
patients with lung squamous cell carcinoma and adenocarcinoma. Moreover, significantly 
negative correlations were also observed between methylation status and mRNA expression 
levels in both sub-types of lung cancer. Taken together, our results provide a strong case that 
this novel genetic variant in DCAF4 was associated with lung cancer risk possibly by decreasing 
gene methylation status that had led to reduced mRNA expression of DCAF4.   
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DCAF4, also known as WDR21, is located on chromosome region 14q24.3 and encodes a 
WD40 repeat protein that interacts with the CUL4 and DDB1 to form the CUL4A-DDB1-DCAF 
complex. This interaction suggests that DCAF4 may be involved in nucleotide excision repair 
(NER), since DDB1 is one key component of the NER pathway, and that the CUL4A-DDBs 
complex may regulate NER activity through ubiquitination of several NER components, e.g., 
DDB2, XPC, and histone H2A at the damaged DNA sites (35,36). Considering that smoking is 
the major risk factor for lung cancer and that smoking caused DNA damage is mainly repaired 
by the NER pathway, the increased DCAF4 expression as a compensation to a high level of 
damage to DNA may not be sufficient for the NER activity and thus result in high risk of lung 
cancer. This may partly explain the underlying biological and molecular mechanisms for the 
observed associations. In addition, DCAF4 may also be involved in the regulation of the 
telomere pathway and influence the telomere length, which is associated with risk of many 
cancers (37). Indeed, SNP rs2535913 in the DCAF4 gene was recently reported to be 
associated with a shorter leucocyte telomere length (38). A shorter telomere length had been 
found to be associated with an increased risk of lung squamous carcinoma and a decreased 
risk of lung adenocarcinoma in one large population study (39) in one recent meta-analysis (40). 
In the present study, we found that the rs2535913 minor A allele (38) also showed a significant 
association with a decreased lung cancer risk (Supplementary Table 3) and a decreased 
DCAF4 expression in adipose tissue and blood cells (GTEx data not shown). This SNP was 
also in a high LD (r2 = 0.78) with one identified functional SNP rs17781739. Although there is 
still no report about functions of DCAF4 on telomerase activity and telomere length, it is known 
that the DDB1 is involved in the regulation of telomerase expression via E2f1 (41,42) and the 
telomerase inhibition through ubiquitination-mediated TERT protein degradation (43). Thus, 
DCAF4 might indirectly influence telomerase activity and telomere length through interaction 
with DDB1 to inhibit the formation of other DDB1 complexes.  
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CRLs mediate the substrate-specific binding in the ubiquitination and play important roles in 
maintaining cellular protein homeostasis, which is especially critical for the lung, as the lung 
often experiences chronic or acute inflammation and frequent immune responses as well as 
DNA damage-repair responses induced by toxic or pathogenic exposures (24,44,45). Previous 
studies have reported that multiple CRL-related genes have been associated with inflammatory 
response and lung cancer. In the present study, in addition to DCAF4, we also found genetic 
variants in nine other CRL-related genes (i.e., COMMD1, CUL5, CUL7, DCAF8, KCTD10, 
KLHL21, KLHL22, PARK2, and TRIM21) to be associated with lung cancer risk with FDR < 0.2.  
Most of these genes were reported as tumor suppressor genes and also involved in the 
inflammation regulation (46-49).  Notably, PARK2 is well studied as a Parkinson disease gene 
located at a fragile region of chromosome 6, which is prone to breakage and rearrangement. 
Genetic changes in this region have been found in several types of tumors, including glioma, 
lung cancer, colorectal, and ovarian cancer (49). We also observed that SNPs in PARK2 are 
associated with lung cancer risk, which might provide some additional biological support for the 
connection between risks of cancer and Parkinson (49,50).  
In the present study, although we revealed associations between multiple genetic variants in 
DCAF4 and lung cancer risk and also provided functional evidence to support these 
associations, the exact biochemical and molecular mechanisms of the effects of those variants 
on DNA methylation and expression as well as possibly inflammation, DNA repair and telomere 
functions are still unclear. The associations between DCAF4 expression levels with telomerase 
activity and telomere length warrant additional experimental validation. Further biochemical 
studies are also required to reveal the hidden mechanisms, such as the role of DCAF4 in DNA 
repair. Although these identified variants only had a moderate effect on lung cancer risk, their 
joint effect might have driven the risk higher, which needs to be further explored in future 
association studies. In addition, as shown in the supplementary data, rs12587742 is significantly 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 17 
associated with DCAF4 mRNA levels in multiple tumor tissues, which implies this SNP might 
have a pleiotropic effect on cancer risk. This also needs to be clarified by future population 
studies across cancers. 
In conclusion, the present study revealed one novel functional genetic variant rs12587742 in 
DCAF4, which is associated with a moderately increased lung cancer risk possibly by 
influencing its gene expression in normal and tumor tissues. We also provided multiple levels of 
evidence to support possible oncogenic effect of DCAF4. Our findings have provided new clues 
for future functional studies to investigate the roles of CRL-related genes in lung carcinogenesis.  
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Figure legends 
Figure 1. Workflow of the study.  
Figure 2. Association results and functional prediction of SNPs in 115 Cullin-ring ligase encoding 
genes. (A) Manhattan plot of the overall results. There were 84 SNPs on 10 CRLs genes with 
nominal P < 0.001 and 28 of them were on the DCAF4 gene with false discovery rate (FDR) < 0.05. 
The x-axis indicated the chromosome number and the y-axis showed the association P values with 
lung cancer risk (as –log10 P values). The horizontal blue line represents P values of 0.001 while 
the red line indicated the FDR threshold 0.05. (B) Regional association plot, which demonstrated 
that the linkage disequilibrium (LD) between the top SNP rs72734410 on DCAF4 and other SNPs in 
the region of 500 kb up- or downstream of the top SNP.  (C) Pair-wise LD plot between the 28 SNPs 
in DCAF4 with FDR < 0.05. Based on it, two tag SNPs (rs17781739 and rs2240980) together with 
one functional SNP rs12587742 were chosen for further analysis. (D) Locations and functional 
prediction of the three chose SNPs. Two SNPs (rs17781739 and rs12587742) are located within 
one CpG island and presented strong signals of active enhancer and promoter functions (indicated 
by DNase hypersensitivity, histone modification H3K27 acetylation and H3K4 methylation, 
respectively). (E) Position weight matrix (PWM) based Sequence Logo, which showed rs12587742 
is located on the c-MYC motif. 
Figure 3. Correlations of the three SNPs with DCAF4 mRNA expression and methylation status in 
blood cells and tumor tissues. Correlation between DCAF4 mRNA expression and (A) rs17781739; 
(D) rs12587742; (G) rs2240980 in 373 blood cells from 373 Europeans individuals in 1000 
genomes project (P = 7.85x10-10, 2.20x10-16 and 8.76x10-6, respectively). Boxplots of DCAF4 mRNA 
expression and (B) rs17781739; (E) rs12587742; (H) rs2240980 in 182 lung squamous cell 
carcinomas (LUSC) tumor tissues from The Cancer Genome Atlas (TCGA) database (P = 0.335, 
0.001 and 0.429, respectively). Boxplots of DCAF4 methylation status and (C) rs17781739; (F) 
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rs12587742; (I) rs2240980 in 157 LUSC tumor tissues from the TCGA database (P = 0.823, 0.032 
and 0.179, respectively).  
Figure 4. Differential mRNA expression and methylation analysis by using the data generated by 
The Cancer Genome Atlas (TCGA). Higher DCAF4 mRNA expression were found in the tumor 
tissues of (A) 156 lung squamous cell carcinomas (LUSC) and (B) 238 adenocarcinomas (LUAD) 
than in the adjacent normal tissues (P = 4.48 x 10-11 and 1.22 x 10-9, respectively). Negative 
correlations were found between DCAF4 methylation and mRNA expression in both the (C) 156 
lung squamous cell carcinomas and (D) 238 adenocarcinomas (P = 0.070 and 8.22 x 10-6, 
respectively).   
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Table 1. Results of the three tagSNPs in the DCAF4 gene with FDR < 0.05 
        
                          Functional prediction 
SNP Position Alleles
1
 MAF # Study # Cases # Controls Effects
2
 OR (95% CI) Pmeta
3
 FDR PQ-test I
2
 SNPinfo
4
 
RegulomDB 
score
5
 
rs17781739 14:73392839 T/G 0.30 6 12160 16838 ------ 0.91 (0.88-0.95) 3.99E-06 0.015 0.665 0 SREBP 4 
rs12587742 14:73393391 A/G 0.21 6 12160 16838 ++++-+ 1.09 (1.05-1.14) 4.97E-05 0.042 0.446 0 MYC/MAX 1a 
rs2240980 14:73409683 G/C 0.32 6 12160 16838 ++++-+ 1.09 (1.05-1.13) 1.44E-05 0.015 0.715 0 NA 3a 
Abbreviations: MAF = minor allele frequency; OR=odds ratio; CI=confidence intervals; FDR=false discovery rate. 
     
1. Effect allele/reference allele 
            
2. "-" indicated protective effect and "+" indicated risk effect of effect alleles in one of the six GWAS studies in the order of: ICR, MDACC, IARC, NCI, Toronto and GLC. 
3. P value from meta-analysis with fixed effects model. 
          
4. Transcription factors with the highest core match score and matrix match score in SNPinfo. 
      
5. The scoring scheme refers to the available datatype for the SNP position: "1a" represents "eQTL + TF binding + matched TF motif + matched DNase Footprint + 
DNase peak"; "3a" represents "TF binding + any motif + DNase peak"; "4" represents "TF binding + DNase peak". 
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Table 2. Stratification analysis of the three identified SNPs by histological types and smoking status. 
       
    Overall   Adenocarcinoma   Squamous cell carcinoma   Never smoking   Ever smoking 
SNP Imp
1
 OR (95% CI)
2
 P
2
   OR (95% CI)
2
 P
2
   OR (95% CI)
2
 P
2
   OR (95% CI)
2
 P
2
   OR (95% CI)
2
 P
2
 
rs17781739 
              
  ICR 0.97 0.96 ( 0.88-1.04) 0.287 
 
1.01 ( 0.87-1.17) 0.880 
 
0.94 ( 0.83-1.08) 0.397 
 
NA NA 
 
NA NA 
  MDACC 0.92 0.95 ( 0.82-1.09) 0.426 
 
0.97 ( 0.82-1.15) 0.745 
 
0.86 ( 0.69-1.07) 0.164 
 
NA NA 
 
0.95 ( 0.82-1.09) 0.426 
  IARC 0.92 0.93 ( 0.85-1.01) 0.088 
 
0.95 ( 0.82-1.11) 0.524 
 
0.98 ( 0.87-1.10) 0.726 
 
0.78 ( 0.59-1.04) 0.089 
 
0.93 ( 0.85-1.02) 0.131 
  NCI 0.97 0.88 ( 0.83-0.93) 2.00E-05 
 
0.88 ( 0.81-0.96) 2.60E-03 
 
0.84 ( 0.77-0.92) 2.14E-04 
 
0.86 (0.69-1.05)
4
 0.154
4
 
 
0.89 (0.83-0.95) 5.31E-04 
  Toronto 0.94 0.88 ( 0.68-1.12) 0.300 
 
0.67 ( 0.46-0.99) 0.043 
 
1.05 ( 0.63-1.76) 0.841 
 
0.89 ( 0.58-1.36) 0.579 
 
0.85 ( 0.62-1.16) 0.308 
  GLC 0.95 0.93 ( 0.76-1.13) 0.455 
 
0.86 ( 0.66-1.14) 0.302 
 
1.04 ( 0.74-1.46) 0.836 
 
0.81 ( 0.42-1.55) 0.522 
 
0.95 ( 0.74-1.23) 0.714 
  Harvard 0.97 0.99 ( 0.91-1.07) 0.752 
 
0.93 ( 0.81-1.06) 0.254 
 
1.15 ( 0.95-1.39) 0.141 
 
1.49 ( 0.96-2.31) 0.075 
 
1.02 ( 0.88-1.20) 0.767 
  Decode 0.95 1.11 ( 0.95-1.30) 0.202 
 
1.11 ( 0.93-1.32) 0.256 
 
1.17 ( 0.89-1.53) 0.273 
 
NA NA 
 
NA NA 
Meta-analysis
3
 0.94 (0.90-0.99) 0.012   0.94 (0.88-1.01) 0.070   0.96 (0.88-1.06) 0.441   0.89 (0.77-1.03) 0.112   0.92 (0.88-0.96) 3.31E-04 
rs12587742 
              
  ICR 0.93 1.12 ( 1.02-1.24) 0.016 
 
1.07 ( 0.9-1.28) 0.423 
 
1.06 ( 0.91-1.24) 0.453 
 
NA NA 
 
NA NA 
  MDACC 0.89 1.18 ( 1.01-1.39) 0.043 
 
1.27 ( 1.05-1.53) 0.015 
 
1.05 ( 0.82-1.36) 0.698 
 
NA NA 
 
1.18 ( 1.01-1.39) 0.043 
  IARC 0.90 1.11 ( 1.01-1.22) 0.033 
 
1.10 ( 0.93-1.31) 0.273 
 
1.18 ( 1.03-1.35) 0.015 
 
1.15 ( 0.85-1.56) 0.356 
 
1.14 ( 1.02-1.27) 0.019 
  NCI 0.94 1.07 ( 1.00-1.14) 0.050 
 
1.04 ( 0.95-1.15) 0.370 
 
1.16 ( 1.05-1.29) 0.005 
 
0.88 (0.69-1.13)
4
 0.331
4
 
 
1.03 (0.96-1.11) 0.394 
  Toronto 0.90 0.88 ( 0.68-1.15) 0.364 
 
0.99 ( 0.65-1.50) 0.965 
 
0.79 ( 0.47-1.33) 0.377 
 
0.62 ( 0.38-1.01) 0.054 
 
1.06 ( 0.76-1.48) 0.746 
  GLC 0.92 1.19 ( 0.94-1.51) 0.143 
 
1.24 ( 0.91-1.70) 0.174 
 
0.90 ( 0.59-1.37) 0.631 
 
1.46 ( 0.75-2.83) 0.266 
 
1.12 ( 0.82-1.53) 0.467 
  Harvard 0.95 1.08 ( 0.98-1.19) 0.137 
 
1.15 ( 0.98-1.34) 0.078 
 
1.29 ( 1.03-1.61) 0.026 
 
1.14 ( 0.72-1.81) 0.579 
 
0.90 ( 0.76-1.07) 0.246 
  Decode 0.91 0.90 ( 0.76-1.07) 0.235 
 
0.90 ( 0.74-1.10) 0.310 
 
0.84 ( 0.62-1.15) 0.283 
 
NA NA 
 
NA NA 
Meta-analysis
3
 1.08 (1.04-1.12) 8.15E-05   1.08 (1.02-1.15) 0.010   1.12 (1.05-1.20) 4.16E-04   0.97 (0.76-1.25) 0.840   1.05 (0.98-1.13) 0.163 
rs2240980 
              
  ICR 0.99 1.11 ( 1.02-1.20) 0.012 
 
1.16 ( 1.00-1.34) 0.052 
 
1.04 ( 0.91-1.18) 0.599 
 
NA NA 
 
NA NA 
  MDACC 0.95 1.14 ( 1.00-1.31) 0.048 
 
1.20 ( 1.03-1.41) 0.021 
 
0.99 ( 0.80-1.22) 0.932 
 
NA NA 
 
1.14 ( 1.00-1.31) 0.048 
  IARC 0.96 1.10 ( 1.02-1.20) 0.017 
 
1.09 ( 0.94-1.27) 0.254 
 
1.14 ( 1.02-1.29) 0.026 
 
1.32 ( 1.02-1.72) 0.035 
 
1.10 ( 1.00-1.20) 0.046 
  NCI 0.99 1.07 ( 1.01-1.13) 0.025 
 
1.07 ( 0.99-1.16) 0.101 
 
1.11 ( 1.01-1.21) 0.030 
 
1.11 (0.90-1.35)
4
 0.325
4
 
 
1.03 (0.97-1.10) 0.317 
  Toronto 0.97 0.94 ( 0.74-1.18) 0.583 
 
1.01 ( 0.70-1.44) 0.968 
 
0.77 ( 0.49-1.21) 0.249 
 
0.82 ( 0.54-1.23) 0.329 
 
1.00 ( 0.74-1.33) 0.979 
  GLC 0.98 1.08 ( 0.88-1.33) 0.455 
 
1.10 ( 0.83-1.44) 0.506 
 
0.88 ( 0.61-1.27) 0.496 
 
1.17 ( 0.64-2.17) 0.607 
 
1.04 ( 0.80-1.36) 0.756 
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  Harvard 0.98 1.08 ( 0.99-1.17) 0.087 
 
1.15 ( 1.01-1.31) 0.036 
 
1.07 ( 0.89-1.29) 0.481 
 
0.87 ( 0.58-1.31) 0.505 
 
0.99 ( 0.86-1.15) 0.933 
  Decode 0.98 0.96 ( 0.83-1.11) 0.566 
 
0.96 ( 0.82-1.13) 0.640 
 
0.92 ( 0.71-1.20) 0.554 
 
NA NA 
 
NA NA 
Meta-analysis
3
 1.08 (1.04-1.11) 1.08E-05   1.10 (1.04-1.15) 3.44E-04   1.07 (1.01-1.13) 0.017   1.08 (0.87-1.34) 0.481   1.05 (0.99-1.11) 0.127 
Abbreviations: Imp = imputation; OR = odds ratio; CI = confidence intervals; ICR = the Institute of Cancer Research Genome-wide Association Study, UK; MDACC = the MD 
Anderson Cancer Center Genome-wide Association Study, US; IARC = the International Agency for Research on Cancer Genome-wide Association Study, France; NCI = the 
National Cancer Institute Genome-wide Association Study, US; Toronto = the Lunenfeld-Tanenbaum Research Institute Genome-wide Association Study, Toronto, Canada; GLC 
= German Lung Cancer Study, Germany; Harvard = Harvard Lung Cancer Study, US; deCODE = Icelandic Lung Cancer Study, Iceland. 
1. Imputation quality score: r-squared from MACH for the MDACC, IARC, GLC and Harvard studies; info values from IMPUTE2 were used in other studies. 
2. Adjusted for the top significant principle components for each study.  
3. Fixed effects model was used in the meta-analysis if Q-test P > 0.1 and heterogeneity statistic I
2
 < 25%; otherwise random effects model. 
4. The pooling results of the four NCI sub-studies: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Cancer Prevention Study II Nutrition Cohort (CPS-
II), the Environment and Genetics in Lung Cancer Etiology (EAGLE), and the Prostate, Lung, Colon, Ovary Screening Trial (PLCO). The detailed results for each sub-study were 
presented on Figure 3. 
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Figure 1 
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Figure 2 
 
  
Ac
ce
pt
ed
 M
an
us
cr
ipt
 33 
Figure 3 
 
 
  
Ac
ce
pt
ed
 M
an
us
cr
ipt
 34 
Figure 4 
 
 
